Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRN | P28799 | 5/20 | 0.72 |
| ▸ | SORT1 | Q99523 | 5/20 | 0.72 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.61 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.61 |
| ▸ | MAPK12 | P53778 | 3/20 | 0.61 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.61 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.52 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.46 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | BRAF | P15056 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18277669 | 0.86 | GRN (0.72) | GRNSORT1MAPK14MAPK13MAPK12 | |
| SCHEMBL1646829 | 0.84 | GRN (1.00) | GRNSORT1MAPK14MAPK13MAPK12 | |
| SCHEMBL16749337 | 0.84 | MAPK14 (0.53) | GRNSORT1MAPK14MAPK13MAPK12 | |
| SCHEMBL16749343 | 0.84 | GRN (0.76) | GRNSORT1MAPK14MAPK13MAPK12 | |
| SCHEMBL2787544 | 0.84 | GRN (0.76) | GRNSORT1MAPK14MAPK13MAPK12 | |
| SCHEMBL2314764 | 0.83 | GRN (0.74) | GRNSORT1MAPK14MAPK13MAPK12 | |
| SCHEMBL16749334 | 0.81 | GRN (0.71) | GRNSORT1MAPK14KLKB1KDM4E | |
| SCHEMBL2906729 | 0.80 | GRN (0.69) | GRNSORT1MAPK14MAPK13MAPK12 | |
| SCHEMBL17449188 | 0.80 | GRN (0.54) | GRNSORT1MAPK14MAPK13MAPK12 | |
| SCHEMBL18277668 | 0.80 | GRN (0.61) | GRNSORT1MAPK14MAPK13MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3074396-B1 | 1-(5-TERT-BUTYL-2-ARYL-PYRAZOL-3-YL)-3-[2-FLUORO-4-[(3-OXO-4H-PYRIDO[2, 3-B]PYRAZIN-8-YL)OXY]PHENYL]UREA DERIVATIVES AS RAF INHIBITORS FOR THE TREATMENT OF CANCER | CANCER RESEARCH TECH LTD (GB) | 2019-05-01 | — | — | EP | disclosed |
| EP-3074396-B1 | 1-(5-TERT-BUTYL-2-ARYL-PYRAZOL-3-YL)-3-[2-FLUORO-4-[(3-OXO-4H-PYRIDO[2, 3-B]PYRAZIN-8-YL)OXY]PHENYL]UREA DERIVATIVES AS RAF INHIBITORS FOR THE TREATMENT OF CANCER | CANCER RESEARCH TECH LTD (GB) | 2019-05-01 | — | — | EP | disclosed |
| US-10167282-B2 | 1-(5-tert-butyl-2-aryl-pyrazol-3-yl)-3-[2-fluoro-4-[(3-oxo-4H-pyrido [2, 3-B]pyrazin- 8-yl)oxy]phenyl]urea derivatives as RAF inhibitors for the treatment of cancer | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-01-01 | — | — | US | disclosed |
| US-10167282-B2 | 1-(5-tert-butyl-2-aryl-pyrazol-3-yl)-3-[2-fluoro-4-[(3-oxo-4H-pyrido [2, 3-B]pyrazin- 8-yl)oxy]phenyl]urea derivatives as RAF inhibitors for the treatment of cancer | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-01-01 | — | — | US | disclosed |
| US-20170298066-A1 | 1 -(5-TERT-BUTYL-2-ARYL-PYRAZOL-3-YL)-3-[2-FLUORO-4-[(3-OXO-4H-PYRIDO[2, 3-B]PYRAZIN-8-YL)OXY]PHENYL]UREA DERIVATIVES AS RAF INHIBITORS FOR THE TREATMENT OF CANCER | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2017-10-19 | — | — | US | disclosed |
| US-20170298066-A1 | 1 -(5-TERT-BUTYL-2-ARYL-PYRAZOL-3-YL)-3-[2-FLUORO-4-[(3-OXO-4H-PYRIDO[2, 3-B]PYRAZIN-8-YL)OXY]PHENYL]UREA DERIVATIVES AS RAF INHIBITORS FOR THE TREATMENT OF CANCER | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2017-10-19 | — | — | US | disclosed |
| US-20170298066-A1 | 1 -(5-TERT-BUTYL-2-ARYL-PYRAZOL-3-YL)-3-[2-FLUORO-4-[(3-OXO-4H-PYRIDO[2, 3-B]PYRAZIN-8-YL)OXY]PHENYL]UREA DERIVATIVES AS RAF INHIBITORS FOR THE TREATMENT OF CANCER | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2017-10-19 | — | — | US | disclosed |
| US-9725447-B2 | 1-(5-tert-butyl-2-aryl-pyrazol-3-yl)-3-[2-fluoro-4-[(3-oxo-4H-pyrido[2,3-b]pyrazin-8-yl)oxy]phenyl]urea derivatives as RAF inhibitors for the treatment of cancer | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2017-08-08 | — | — | US | disclosed |
| US-9725447-B2 | 1-(5-tert-butyl-2-aryl-pyrazol-3-yl)-3-[2-fluoro-4-[(3-oxo-4H-pyrido[2,3-b]pyrazin-8-yl)oxy]phenyl]urea derivatives as RAF inhibitors for the treatment of cancer | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2017-08-08 | — | — | US | disclosed |
| US-9725447-B2 | 1-(5-tert-butyl-2-aryl-pyrazol-3-yl)-3-[2-fluoro-4-[(3-oxo-4H-pyrido[2,3-b]pyrazin-8-yl)oxy]phenyl]urea derivatives as RAF inhibitors for the treatment of cancer | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2017-08-08 | — | — | US | disclosed |
| US-20160355510-A1 | 1 -(5-TERT-BUTYL-2-ARYL-PYRAZOL-3-YL)-3-[2-FLUORO-4-[(3-OXO-4H-PYRIDO[2, 3-B]PYRAZIN-8-YL)OXY]PHENYL]UREA DERIVATIVES AS RAF INHIBITORS FOR THE TREATMENT OF CANCER | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-12-08 | — | — | US | disclosed |
| US-20160355510-A1 | 1 -(5-TERT-BUTYL-2-ARYL-PYRAZOL-3-YL)-3-[2-FLUORO-4-[(3-OXO-4H-PYRIDO[2, 3-B]PYRAZIN-8-YL)OXY]PHENYL]UREA DERIVATIVES AS RAF INHIBITORS FOR THE TREATMENT OF CANCER | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-12-08 | — | — | US | disclosed |
| US-20160355510-A1 | 1 -(5-TERT-BUTYL-2-ARYL-PYRAZOL-3-YL)-3-[2-FLUORO-4-[(3-OXO-4H-PYRIDO[2, 3-B]PYRAZIN-8-YL)OXY]PHENYL]UREA DERIVATIVES AS RAF INHIBITORS FOR THE TREATMENT OF CANCER | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-12-08 | — | — | US | disclosed |
| EP-3074396-A1 | 1 -(5-TERT-BUTYL-2-ARYL-PYRAZOL-3-YL)-3-[2-FLUORO-4-[(3-OXO-4H-PYRIDO[2, 3-B]PYRAZIN-8-YL)OXY]PHENYL]UREA DERIVATIVES AS RAF INHIBITORS FOR THE TREATMENT OF CANCER | Cancer Research Technology Ltd (GB) | 2016-10-05 | — | — | EP | disclosed |
| WO-2015075483-A1 | 1 -(5-TERT-BUTYL-2-ARYL-PYRAZOL-3-YL)-3-[2-FLUORO-4-[(3-OXO-4H-PYRIDO[2, 3-B]PYRAZIN-8-YL)OXY]PHENYL]UREA DERIVATIVES AS RAF INHIBITORS FOR THE TREATMENT OF CANCER | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2015-05-28 | — | — | WO | disclosed |
| WO-2015075483-A1 | 1 -(5-TERT-BUTYL-2-ARYL-PYRAZOL-3-YL)-3-[2-FLUORO-4-[(3-OXO-4H-PYRIDO[2, 3-B]PYRAZIN-8-YL)OXY]PHENYL]UREA DERIVATIVES AS RAF INHIBITORS FOR THE TREATMENT OF CANCER | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2015-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170298066-A1 | 1 -(5-TERT-BUTYL-2-ARYL-PYRAZOL-3-YL)-3-[2-FLUORO-4-[(3-OXO-4H-PYRIDO[2, 3-B]PYRAZIN-8-YL)OXY]PHENYL]UREA DERIVATIVES AS RAF INHIBITORS FOR THE TREATMENT OF CANCER | BRAF, NRAS, LCK | GRN 2980/4885SORT1 3325/4885MAPK14 80/4885 |
| US-20160355510-A1 | 1 -(5-TERT-BUTYL-2-ARYL-PYRAZOL-3-YL)-3-[2-FLUORO-4-[(3-OXO-4H-PYRIDO[2, 3-B]PYRAZIN-8-YL)OXY]PHENYL]UREA DERIVATIVES AS RAF INHIBITORS FOR THE TREATMENT OF CANCER | BRAF, NRAS, LCK | GRN 3058/4885SORT1 3244/4885MAPK14 67/4885 |
| US-10167282-B2 | 1-(5-tert-butyl-2-aryl-pyrazol-3-yl)-3-[2-fluoro-4-[(3-oxo-4H-pyrido [2, 3-B]pyrazin- 8-yl)oxy]phenyl]urea derivatives as RAF inhibitors for the treatment of cancer | BRAF, NRAS, LCK | GRN 2980/4885SORT1 3325/4885MAPK14 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.